Epstein-barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue

American Journal of Pediatric Hematology/Oncology

Volumn 24, Issue 2, 2002, Pages 160-163

  Heath, John A ^a   Broxson, Emmett H ^b   Dole, Mukund G ^b   Filippa, Daniel A ^a   George, Diane ^a   Lyden, David ^a   Dunkel, Ira J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CHILDREN S MEDICAL CENTER   (United States)

Author keywords

Bone marrow transplantation; Epstein Barr virus; Lymphoma; Lymphoproliferative disease; Retinoblastoma

Indexed keywords

ACICLOVIR; ALKYLATING AGENT; CYTOMEGALOVIRUS ANTIBODY; MYELOABLATIVE AGENT; RITUXIMAB;

ANAMNESIS; ANTIBODY TITER; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CASE REPORT; CERVICAL LYMPH NODE; DIFFERENTIAL DIAGNOSIS; EPSTEIN BARR VIRUS; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; LYMPHADENOPATHY; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; RETINOBLASTOMA; STEM CELL TRANSPLANTATION;

ACYCLOVIR; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIVIRAL AGENTS; CARBOPLATIN; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; EPSTEIN-BARR VIRUS INFECTIONS; ETOPOSIDE; EYE ENUCLEATION; EYE NEOPLASMS; FATAL OUTCOME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MENINGEAL NEOPLASMS; METHYLPREDNISOLONE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; OPTIC NERVE NEOPLASMS; RADIOTHERAPY, ADJUVANT; RETINOBLASTOMA; THIOTEPA; VINCRISTINE;

EID: 0036168523     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200202000-00022     Document Type: Article

References (24)

1. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B-cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-43.
2. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989; 321: 784-9.
3. Young L, Alfieo C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989; 321: 1080-5.
4. Chao NJ, Berry GJ, Advani R, et al. Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin’s lymphoma. Transplantation 1993; 55: 1425-8.
5. Shepherd JD, Gascoyne RD, Barnett MJ, et al. Polyclonal Epstein-Barr virus-associated lymphoproliferative disorder following autografting for chronic myeloid leukemia. Bone Marrow Transplant 1995; 15: 639-41.
6. Briz M, Fores R, Regidor C, et al. Epstein-Barr virus associated B-cell lymphoma after autologous bone marrow transplantation for T-cell acute lymphoblastic leukemia. Br J Haematol 1997; 98: 485-7.
7. Hauke RJ, Greiner TC, Smir BN, et al. Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: a report of two cases. Bone Marrow Transplant 1998; 21: 1271-4.
8. Joncas JH, Russo P, Brochu P, et al. Epstein-Barr virus polymorphic B-cell lymphoma associated with leukemia and with congenital immunodeficiencies. J Clin Oncol 1990; 8: 378-84.
9. Saemundsen AK, Purtilo DT, Sakamoto K, et al. Documentation of Epstein-Barr virus infection in immunodeficient patients with life-threatening lymphoproliferative disease by Epstein-Barr virus complementary RNA/DNA and DNA/RNA hybridization. Cancer Res 1981; 41: 4237-42.
10. Saemundsen AK, Berkel AI, Henle W, et al. Epstein-Barr virus carrying lymphoma in a patient with ataxia telangiectasia. Br J Haematol 1981; 282: 425-7.
11. Seiden MV, Sklar J. Molecular genetic analysis of post-transplant lymphoproliferative disorders. Hematol Oncol Clin North Am 1993; 7: 447-65.
12. Nalesnik MA. Posttransplantation lymphoproliferative disorders (PTLD): current perspectives. Semin Thorac Cardiovasc Surg 1996; 8: 139-48.
13. Briz M, Fores R, Regidor C, et al. Epstein-Barr virus associated B-cell lymphoma after autologous bone marrow transplantation for T-cell acute lymphoblastic leukemia. Br J Haematol 1997; 98: 485-7.
14. Look AT, Naegele RF, Callihan T, et al. Fatal Epstein-Barr virus infection in a child with acute lymphoblastic leukemia in remission. Cancer Res 1981; 41: 4280-3.
15. Hardy C, Feusner J, Harada S, et al. Fatal Epstein-Barr virus-induced lymphoproliferation complicating acute lymphoblastic leukemia. J Pediatr 1984; 105: 64-7.
16. Mustafa MM, Winick NJ, Margraf LR. Epstein-Barr virus lymphoproliferative disorder in children with leukemia: case report and review of the literature. J Pediatr Hematol Oncol 1997; 19: 77-81.
17. Buckingham SC, Benaim E, Sandlund JT, et al. Primary central nervous system lymphoma in a child with acute B-cell lymphoblastic leukemia: consecutive Epstein-Barr virus-related malignancies. Br J Haematol 1998; 101: 345-8.
18. Perkkio M, Riikonen P, Seuri R, et al. Successful treatment of monoclonal, aggressive Epstein-Barr virus-associated B-cell lymphoproliferative disorder in a child with acute lymphoblastic leukemia. Med Pediatr Oncol 1999; 32: 447-9.
19. Drury SS, Sathiapalan RK, Warrier RP. Central nervous system involvement of Epstein-Barr virus lymphoproliferative disease in a patient with acute lymphocytic leukemia. J Pediatr Hematol Oncol 2000; 22: 167-70.
20. Sung L, Dix D, Allen U, et al. Epstein-Barr virus-associated lymphoproliferative disorder in a child undergoing therapy for localized rhabdomyosarcoma. Med Pediatr Oncol 2000; 34: 358-60.
21. Maloney D, Smith B, Appelbaum F. The anti-tumor effect of monoclonal anti-CD20 antibody (MAB) therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin’s lymphoma (NHL) cell lines (abstract). Blood 1996; 88: 637a.
22. Davis TA, White CA, Grillo-Lopez AJ, et al. Single-agent monoclonal antibody efficacy in bulky non-Hodgkin’s lymphoma: results of a phase II trial of rituximab. J Clin Oncol 1999; 17: 1851-7.
23. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation. Blood 2000; 95: 1502-5.
24. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92: 1549-55.